NCT02945579 - Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

January 20, 2017

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Estrogen Receptor NegativeHER2 Positive Breast CarcinomaHER2/Neu NegativeInvasive Breast CarcinomaProgesterone Receptor NegativeStage I Breast Cancer AJCC v7Stage IA Breast Cancer AJCC v7Stage IB Breast Cancer AJCC v7Stage II Breast Cancer AJCC v6 and v7Stage IIA Breast Cancer AJCC v6 and v7Stage IIB Breast Cancer AJCC v6 and v7Triple-Negative Breast Carcinoma

Interventions

RADIATION

Undergo EBRT

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

RADIATION

Partial Breast Irradiation

Undergo partial breast irradiation

Trial Locations (8)

15232

RECRUITING

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

28203

RECRUITING

Carolinas Medical Center/Levine Cancer Institute, Charlotte

32207

RECRUITING

Baptist MD Anderson Cancer Center, Jacksonville

55905

RECRUITING

Mayo Clinic, Rochester

77030

RECRUITING

M D Anderson Cancer Center, Houston

85234

COMPLETED

MD Anderson Cancer Center - Banner, Gilbert

96813

COMPLETED

Queen's Medical Center, Honolulu

08103

RECRUITING

Cooper Hospital Univ Med Ctr, MD Anderson at Cooper Voorhees, Voorhees Township